Related Experiment Video
Updated: Aug 13, 2025
Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids
Published on: August 18, 2023
Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening
Cuiying Xie1,2, Ancheng Gu1,2, Muhammad Khan3
1Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Abstract:
Hepatocellular carcinoma is one of the malignancies worldwide with a high mortality rate and an increasing incidence. Molecular Targeted agents are its common first-line treatment. Organoid technology, as a cutting-edge technology, is gradually being applied in the development of therapeutic oncology. Organoid models can be used to perform sensitivity screening of targeted drugs to facilitate the development of innovative therapeutic agents for the treatment of hepatocellular carcinoma. The purpose of this review is to provide an overview of the opportunities and challenges of hepatocellular carcinoma organoids in targeted drug sensitivity testing as well as a future outlook.
Insights
Hepatocellular carcinoma organoids offer a promising approach for targeted drug sensitivity testing. This review explores their potential and challenges in advancing hepatocellular carcinoma treatment.
Area of Science:
- Oncology
- Biotechnology
- Drug Development
Background:
- Hepatocellular carcinoma (HCC) is a global malignancy with high mortality and rising incidence.
- Molecular targeted agents are a primary treatment for HCC.
- Organoid technology is emerging as a key tool in therapeutic oncology.
Purpose of the Study:
- To review the application of HCC organoids in targeted drug sensitivity testing.
- To discuss the opportunities and challenges associated with this technology.
- To provide a future outlook for HCC organoid development.
Main Methods:
- Review of current literature on hepatocellular carcinoma organoids.
- Analysis of organoid applications in targeted drug screening.
- Exploration of challenges and future directions in the field.
Main Results:
- Organoid models show potential for personalized sensitivity screening of targeted drugs in HCC.
- Organoid technology can facilitate the development of novel therapeutic agents.
- Challenges include standardization, scalability, and clinical validation.
Conclusions:
- Hepatocellular carcinoma organoids represent a significant advancement for personalized medicine in HCC treatment.
- Further research is needed to overcome current limitations and fully realize their therapeutic potential.
- Organoids are poised to play a crucial role in the future of targeted cancer therapy.
